Numerous physiological conditions and emotionally motivated behaviors require concomitant activation of somatomotor and sympathetic efferents. Using a virally mediated retrograde transsynaptic tract-tracing approach, we have previously determined locations of presympathetic-premotor neurons (PSPMNs) in the rat brainstem. These putative dualfunction neurons send projections to somatomotor and sympathetic targets and likely participate in sympatho-somatomotor integration. A significant portion of these neurons is found within brainstem areas known to contain serotonergic neurons. Thus, we hypothesized that some of the PSPMNs utilize serotonin as their neurotransmitter. To test this hypothesis we first produced an antibody against TPH2, a brain-specific isoform of tryptophan hydroxylase (serotonin synthetic enzyme). We identified PSPMNs by using recombinant strains of the pseudorabies virus (PRV) for transsynaptic tract-tracing. PRV-152, a strain that expresses enhanced green fluorescent protein, was injected into sympathectomized gastrocnemius muscle, while PRV-BaBlu, which expresses ␤-galactosidase, was injected into the adrenal gland in the same animals. Using immunofluorescent methods we determined whether coinfected neurons expressed TPH2. Our findings demonstrate that TPH2-positive PSPMNs are present at different rostrocaudal levels of the brainstem. Just over half of them are found at the pontomedullary junction within raphe obscurus, raphe magnus, and gigantocellular nucleus pars alpha. These cells may play a role in mediating responses to acute pain stimuli and/or participate in the central control of exercise. Overactivity of these serotonergic sympatho-somatomotor circuits may also play a role in the pathophysiology of serotonin syndrome.
A wide range of human and animal behaviors are characterized by coordinated activation or inhibition of the activity of somatomotor efferents and that of the sympathetic nervous system. Such behaviors can be divided into several categories, including those that: 1) support daily physiological functions of the organism, 2) are part of motivated behaviors, and 3) are part of emotionally driven responses. Examples of behaviors in the first category include locomotion, exercise, cold defense, and sleep. Each of these behaviors is characterized by a specific and coordinated pattern of sympathetic and somatomotor activity. In the case of locomotion, or other forms of exercise, the onset of rhythmic somatomotor discharge is accompanied by an immediate increase in respiratory function as well as increases in heart rate, stroke volume, cardiac output, peripheral resistance, and blood pressure to improve oxygen delivery to contracting muscles (Waldrop et al., 1996) . Likewise, cold defense is characterized by increased shivering together with an increase in activity of sympathetic nerves innervating brown adipose tissue (Morrison, 2004) . Motivated behaviors are likewise characterized by somatomotor and autonomic activation, such as during feed-ing behavior when activation of visceral efferents to the gut needs to be coordinated with that of the somatomotor efferents innervating muscles of mastication (Sutcliffe and de Lecea, 2000) . Furthermore, emotionally motivated behaviors are characterized by concomitant recruitment of somatomotor and sympathetic efferents. For example, aggressive/defensive behavior may be characterized by hissing, alerting, turning of the head, and kicking or striking together with increases in blood pressure and heart rate as well as complementary redistribution of systemic blood flow (Mancia and Zanchetti, 1981; Hilton, 1982; Jordan, 1990) .
Despite such compelling behavioral examples, traditional views on the neural control of the sympathetic and somatomotor systems have posited that these are regulated by very different neural networks. In such a scheme the somatic motor system is viewed to be largely under voluntary control and is regulated by voluntary action (Cannon, 1963) . In contrast, the function of the internal viscera is viewed as largely outside of the willful control of the body and was thought to be regulated subconsciously by the sympathetic and parasympathetic arms of the autonomic nervous system (Langley, 1921; Cannon, 1963) . More recent anatomical investigations have challenged this notion and have provided evidence against this arbitrary separation between somatomotor and autonomic systems. Specifically, Holstege (1995) suggested the existence of an emotional motor system, which coordinates somatic motoneuron activity as part of emotionally motivated behaviors. Work in our laboratory has sought to extend these findings by directly addressing the question of whether neurons with dual sympathetic and somatomotor functions exist. Using genetically engineered strains of the pseudorabies virus (PRV), we previously identified distinct populations of neurons that simultaneously send transsynaptic projections to the adrenal gland and the gastrocnemius muscle; populations of such cells were distributed throughout the neuraxis and included areas in the medulla, pons, midbrain, hypothalamus, and cortex (Kerman et al., 2003 (Kerman et al., , 2006 . A major brainstem area containing such presympathetic-premotor neurons (PSPMNs) was located within several nuclei that comprise the ventromedial medulla, including the caudal raphe nuclei (raphe obscurus, raphe pallidus, and raphe magnus), gigantocellular nucleus pars alpha, and the ventral gigantocellular nucleus (Kerman et al., 2003) . These ventromedullary nuclei contain large numbers of serotonergic neurons that send descending projections to the spinal cord (Mason, 2001 ). More rostrally, we identified another major cluster of PSPMNs in the caudal portion of the ventrolateral periaqueductal gray (Kerman et al., 2006) . Similar to the ventromedial medulla, this area has also been reported to contain a population of serotonergic neurons (Steinbusch, 1981) .
Taken together, these observations suggest that a subset of the PSPMNs in the brainstem may use serotonin as their neurotransmitter. To test this hypothesis we utilized a previously developed paradigm for the identification of PSPMNs by using virally mediated transsynaptic tract tracing (Kerman et al., 2003 (Kerman et al., , 2006 together with immunofluorescent detection of tryptophan hydroxylase (TPH), a key synthetic enzyme in the production of serotonin (Nestler et al., 2001) . Two isoforms of TPH have been described, TPH1 and TPH2 (Walther et al., 2003) ; only the latter is expressed in the brain (Patel et al., 2004) . Thus, to test our hypothesis we generated an antibody specific for TPH2.
MATERIALS AND METHODS
All of the procedures regarding animal use in this study conformed to the Guide for the Care and Use of Laboratory Animals (1996, National Academy of Sciences) and were approved by the University of Michigan's University Committee on Use and Care of Animals.
Design and characterization of the TPH2 antibody
Our initial experiments were aimed at designing an antibody against TPH and then validating the specificity of its binding in paraformaldehyde-fixed rat tissue. The TPH1 isoform is preferentially expressed in the periphery and the pineal gland, while TPH2 is expressed within the brainstem raphe nuclei (Walther et al., 2003; Patel et al., 2004) . To avoid crossreactivity with other hydroxylases, our antibody was designed specifically to avoid the active core of TPH2. Instead, it targeted a unique span of the N-terminal region: Phe-Ser-Leu-Asp-Ser-Ala-Val-ProGlu-Glu-His-Gln, which was crosslinked to thyroglobulin using glutaraldehyde. The antibody was raised by injection of the conjugated peptide into a rabbit. Serum was then collected and booster inoculations were administered every 6 weeks. The current experiments were carried out with serum obtained from the sixth bleed, which was affinity-purified. Specificity of the rabbit anti-TPH antibody was confirmed in adult male Sprague-Dawley rats (n ϭ 2; Charles River Laboratories, Wilmington, MA). In these experiments the animals were deeply anesthetized with 1-1.5 mL intraperitoneal (i.p.) of 50 mg/mL pentobarbital sodium solution. Rats were then transcardially perfused with 100 -150 mL of physiological saline followed by 400 -500 mL of Zamboni's fixative (1.8% paraformaldehyde, 0.075% of picric acid in 0.17 M phosphate buffer, PB). Brains were then extracted, 10-m brain sections were cut on a cryostat at Ϫ20°C, and mounted on Superfrost slides (Fisher Scientific, Pittsburgh, PA) immediately after sectioning. TPH2 antibody was reacted with the tissue at multiple concentrations and the optimal dilution was empirically determined. Using the nickelenhanced horseradish peroxidase diaminobenzidine visualization procedure the optimal dilution of the antibody was 1:2,000. The distribution pattern of TPH2 immunoreactivity was examined under control conditions and under conditions when the antibody was preincubated with various peptides. In these experiments adjacent sections were incubated with the TPH2 antibody and with the TPH2 antibody solution preincubated with 2 M and 5 M of the TPH2 peptide (see sequence above). In similar experiments, adjacent sections were incubated the TPH2 antibody and with the TPH2 antibody solution preincubated with 2 M and 5 M of TPH1 peptide (Met-Ile-Glu-AspAsn-Lys-Glu-Asn-Lys-Asp-His-Ser-Leu-Glu-Arg) or preincubated with 1 M or 50 M of Ki-67 (Thr-Pro-Lys-GluLys-Ala-Gln-Ala-Leu-Glu-Asp-Leu-Ala-Gly-Phe-Lys-GluLeu-Phe-Gln-Thr-Pro), an unrelated peptide.
To determine the fraction of TPH2-positive cells within the different nuclei, one adult male Sprague-Dawley rat was deeply anesthetized with 1 mL i.p. of 50 mg/mL penThe Journal of Comparative Neurology. DOI 10.1002/cne tobarbital sodium solution and then transcardially perfused with 150 mL of physiological saline followed by 500 mL of a 4% paraformaldehyde solution containing 1.4% L-lysine and 0.2% sodium meta-periodate (PLP fixative) (McLean and Nakane, 1974) . The brain was then extracted, postfixed overnight, immersed in 30% sucrose until it sank, and cut on a freezing microtome at a thickness of 40 m. A 1-in-6 series was then reacted with the TPH2 antibody at a concentration of 1:2,000 overnight and visualized with diaminobenzidine. The sections were then mounted on glass slides, counterstained with cresyl violet, dehydrated in graded alcohols, defatted in xylene, and coverslipped with Permount (Fisher Scientific).
Overview of tract-tracing studies
Male Sprague-Dawley rats (n ϭ 6) (Charles River Laboratories, Wilmington, MA) were used in tract-tracing studies. In these experiments we employed transgenic recombinants of an attenuated PRV strain, PRV-Bartha, for transneuronal tracing of multisynaptic pathways innervating adrenal gland and gastrocnemius muscle. PRV has preferential tropism for axonal terminals (Vahlne et al., 1978 (Vahlne et al., , 1980 . It is transported in the retrograde direction from the terminals to the cell body where the viral genome is replicated in the nucleus (Enquist et al., 1998) . Capsids are assembled and filled with viral DNA in the nucleus, acquire the mature envelope from a late Golgi compartment, and are transported to sites of afferent synaptic contact where cell-to-cell retrograde transneuronal transmission of infection occurs (Card et al., 1993; Enquist et al., 1998) . The two viral recombinants that we employed were PRV-152 and PRV-BaBlu. Both are derived from PRV-Bartha, which is an attenuated form of the parental strain, PRV-Becker. PRV-BaBlu contains the lac Z gene at the gG locus and produces ␤-galactosidase (␤-gal) under the control of the viral gG promoter (Kim et al., 1999) . PRV-152 carries the gene coding for enhanced green fluorescent protein (eGFP) at the gG locus, which is constitutively expressed under control of the cytomegalovirus immediate early promoter (Smith et al., 2000) . Previous studies have demonstrated that PRV-152 and PRV-BaBlu are transported transsynaptically in a retrograde manner, similar to PRV-Bartha, and that the two recombinants are capable of simultaneously coinfecting the same neuronal population (Standish et al., 1995; Billig et al., 1999 Billig et al., , 2000 Billig et al., , 2001 Smith et al., 2000; Kerman et al., 2003 Kerman et al., , 2006 .
We previously reported a robust negative correlation between an animal's weight and efficiency of infection of gastrocnemius motoneurons, with the largest rate of motoneuron infection in rats of intermediate size that weigh ϳ200 g (Kerman et al., 2003) . Thus, animals in the current study were selected to weigh between 163 and 240 g for an average of 194 Ϯ 13 g (mean Ϯ SEM; weighed at time of sympathectomy (see below)). Animals were anesthetized with 5% isoflurane vaporized in 1-1.5 L/min of O 2 , and maintained with a 1.5-2.5% concentration. Once a surgical plane of anesthesia was achieved such that there was no spontaneous movement and there were no withdrawal responses to tail and/or foot pinch, hindlimb sympathectomy was performed.
In addition to somatic motor efferents, the hindlimb is also innervated by sympathetic efferents that project to blood vessels, sweat glands, and other smooth muscle targets (Jä nig and McLachlan, 1992) . To prevent infection of sympathetic pathways following injection of PRV-152 into the gastrocnemius muscle, the hindlimb was surgically sympathectomized in all animals using a previously described approach (Kerman et al., 2003) . Briefly, the lumbar sympathetic nerve was dissected via a ventral laparotomy and was extirpated from the level of the renal artery caudal to the bifurcation of the abdominal aorta. Neural plexuses running along the descending aorta and inferior vena cava were also stripped off under microscopic observation using fine forceps. The abdominal aorta and the inferior vena cava were then swabbed with 10 -20% phenol dissolved in ethylene glycol. The abdominal musculature was closed with sutures and the overlying skin was closed with surgical staples. This procedure is effective at removing the large majority of sympathetic efferents to the hindlimb, as evidenced by the lack of infection in the intermediolateral cell column in the same animals that exhibited robust infections of lumbar motoneurons (Kerman et al., 2003 (Kerman et al., , 2006 .
Following sympathectomy and a 2-10 day recovery period the animals were reanesthetized. Due to supply problems some of the animals (n ϭ 2) were anesthetized with an i.p. injection of ketamine and xylazine mixture (60 mg/kg ketamine and 7 mg/kg xylazine), while the remaining animals were anesthetized using an isoflurane protocol as described above. After a surgical plane of anesthesia was achieved the animals were injected with PRV-152 into their gastrocnemius muscle.
Following PRV-152 injections and a 24 -32-hour recovery period the same rats were reanesthetized with either isoflurane (n ϭ 4) or a ketamine and xylazine mixture (n ϭ 2) and were injected with PRV-BaBlu into the adrenal glands. Choice of anesthetic regime had no effect on viral infection or transport.
At the conclusion of the survival period following transport of viral tracers, animals were deeply anesthetized with 1 mL i.p. of 50 mg/mL pentobarbital sodium solution and transcardially perfused with 100 -150 mL of physiological saline followed by 400 -500 mL of PLP fixative.
Double-virus injections
Viral recombinants used in the present studies were harvested from pig kidney cell cultures at a titer of 10 8 -10 9 pfu/mL. Viral stocks were aliquoted in 50-L volumes and stored at Ϫ80°C. At the times of injection viral aliquots were removed from the freezer and kept on ice until immediately before injections.
To determine the location of neurons coordinating muscle contraction and autonomic activity, rats received injections of PRV-152 into their left (n ϭ 4) or right (n ϭ 2) gastrocnemius muscle and injections of PRV-BaBlu into their left adrenal gland (n ϭ 6). The gastrocnemius muscle was injected with 30 L of PRV-152, which was divided into multiple injections of 1.0 L. The adrenal gland was dissected via a left flank incision and gently separated from surrounding viscera and fat; the adjacent connective tissue was then retracted to facilitate access to the gland. Two or three injections of PRV-BaBlu were then made into the gland through a glass pipette attached to a 10-L Hamilton syringe; the total volume of virus injected was 2-4 L. Following each injection the gland was swabbed with a cotton-tip applicator to decrease nonspecific viral spread. We previously demonstrated that this injection protocol produces an efficient infection of target neurons and does not result in spread of virus to nontarget tissues (Kerman et al., 2003) .
Injected animals were assigned to one of three groups: short, intermediate, and long survival times. In the short survival group (n ϭ 2) rats survived 121-122 hours following injections with PRV-152 and 96 -97 hours following PRV-BaBlu injections. We chose these survival time points because this is one of the earliest time points at which appreciable numbers of double-infected neurons are detected in the ventromedial medulla in the rat (Kerman et al., 2003 (Kerman et al., , 2006 . Since a single replication cycle of the virus is 10 -12 hours (Demmin et al., 2001) , we therefore decided to extend the survival times by 10 -12 hours to determine the maximal number of double-infected neurons that express TPH2. Accordingly, in the intermediate survival group (n ϭ 2) the animals survived 132 and 108 hours following injections with PRV-152 and PRV-BaBlu, respectively. In the late survival group (n ϭ 2) the animals survived 144 and either 112 or 120 hours following injections with PRV-152 and PRV-BaBlu, respectively.
Tissue processing
Following transcardial perfusion with PLP (see above), the entire brain was extracted and postfixed in PLP overnight. Brains were then immersed in 30% sucrose until they sank to the bottom of the container and sectioned coronally on a freezing microtome at a thickness of 35 or 40 m and collected into six bins. Tissue was stored at Ϫ20°C in cryoprotectant (30% sucrose, 30% ethylene glycol, 1% polyvinyl-pyrrolidine (PVP-40)) until immunohistochemical processing was conducted.
In two animals (both in the short survival group) thoracic and lumbar spinal cords were also collected. In these animals spinal cord was extracted in three blocks: T1-T7 segment, T8 -T13, and L1-L6. These blocks were then sectioned in the horizontal plane at 35 or 40 m. A onein-three series for each block was processed for simultaneous visualization of PRV-152 and PRV-BaBlu using immunofluorescent methods aimed at the detection of eGFP and ␤-gal (see below for methodological details).
For immunofluorescent detection in the brain, tissue was initially rinsed with 0.1 M PB (pH 7.4) several times at room temperature. It was then incubated for 1 hour in a blocking solution made up of 1% normal goat serum (NGS), 1% bovine serum albumin (BSA), and 0.3% Triton X-100 (TX-100) in 0.1 M PB. Sections were then reacted with a cocktail of primary antibodies: chicken anti-GFP IgY (Abcam, Cambridge, MA, product 13970) at 1:2,000, mouse anti-␤-gal IgG (Sigma, St. Louis, MO, product G4644) at 1:1,000, and rabbit anti-TPH2 at 1:500, diluted in the above blocking solution. The chicken anti-GFP antibody was raised against recombinant full-length protein. This antibody yields a single band on Western blot and detects GFP in transgenic mice expressing GFP in lamina II of the spinal cord (manufacturer's technical information). In our preliminary experiments we demonstrated the absence of staining with this antibody in uninfected rat tissue sections. Mouse anti-␤-gal antibody was developed in mouse peritoneal cavities using ␤-gal purified from E. coli as the immunogen. Using Western blot, this antibody was shown to be specific for ␤-gal in its native form (116 kD), and it reacts only with ␤-gal from E. coli (manufacturer's technical information). Specificity of this antibody in immunofluorescent experiments has been previously documented (Kerman et al., 2003) .
Following a 24 -48-hour incubation at 4°C in the primary antibody solution, the tissue was rinsed several times with 0.1 M PB and then reacted with a secondary antibody solution, which consisted of donkey anti-mouse IgG conjugated to CY3 (1:200; Jackson ImmunoResearch, West Grove, PA), goat anti-chicken IgG conjugated to AlexaFluor488 (1:200; Molecular Probes, Eugene OR, Invitrogen, La Jolla, CA) and biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA) dissolved in the blocking solution (1% NGS, 1% BSA, and 0.3% TX-100). Tissue sections were then briefly rinsed and then incubated with NeutrAvidin conjugated to AlexaFluor350 (1:200; Molecular Probes, Invitrogen). Thus, PRV-152-infected cells appeared green, those infected with PRVBaBlu were red, while TPH2-positive neurons were blue. Neurons double-infected with PRV-152 and PRV-BaBlu appeared either yellow or orange, depending on the balance of colors. Double-infected cells that colocalized with TPH2 would theoretically be white, since blue, green, and red represent the full spectrum of visible light. However, because of the differences in the balance and intensity of each color, triple-labeled cells were close to white in color with a bluish, reddish, or greenish tinge to them. Following processing, tissue sections were mounted on glass slides and coverslipped with Aqua Poly/Mount (Polysciences, Warrington, PA).
For immunofluorescent detection in the spinal cord a similar protocol was used. Tissue was initially rinsed with 0.1 M PB several times at room temperature. It was then incubated for 1 hour in a blocking solution made up of 1% normal donkey serum, 1% BSA, 0.3% TX-100 in 0.1 M PB. The tissue was then reacted with a cocktail of primary antibodies: rabbit anti-GFP IgG (Molecular Probes) at 1:1,000 and mouse anti-␤-gal IgG (Sigma) at 1:1,000, diluted in the above blocking solution. Following a 24 -48-hour incubation at 4°C in the primary antibody solution the tissue was rinsed several times with 0.1 M PB and then reacted with a secondary antibody solution, which consisted of donkey anti-mouse IgG conjugated to CY3 (1:200; Jackson ImmunoResearch) and goat anti-rabbit IgG conjugated to BODIPY FL (1:200; Molecular Probes) dissolved in the blocking solution. Thus, PRV-152-infected cells appeared green, while those infected with PRVBaBlu were red. Specificity of the primary and secondary antibodies employed in these double-labeling experiments has been previously documented (Billig et al., 2000; Kerman et al., 2003) .
Tissue analysis
Tissue was examined using a Leica DMR photomicroscope (Wetzlar, Germany). The rat atlas of Paxinos and Watson (1986) was used as a reference for anatomical classification. Infected neurons were digitized using a Photometrics CoolSNAP fx black-and-white camera (Tucson, AZ) and MCID Elite 7.0 imaging software (Imaging Research, St. Catharines, Ontario). The presence of each fluorophore was detected using specific filter sets (Chroma Technology, Brattleboro, VT) with the following respective excitation and emission ranges: AlexaFluor350: 320 -400 nm and 410 -510 nm (blue fluorescence), AlexaFluor488 and BODIPY FL: 440 -520 nm and 500 -555 nm (green fluorescence), and CY3: 535-560 nm and 545-625 nm (red fluorescence).
Adjacent black-and-white images of the region of interest were digitized under a 20ϫ objective using a manually driven stage equipped with a Leica Sensor Control Display (Mä rzhä user SensoTech, Wetzlar, Germany) to
The Journal of Comparative Neurology. DOI 10.1002/cne record stage coordinates. We took several high-power images through the region of interest. In order to visualize the entire area, high-power images were stitched together using the Photomerge function in Adobe Photoshop v. 8.0 (Adobe Systems, San Jose, CA). Each of these large stitched images corresponded to a different fluorescent filter set and was pseudocolored as follows: GFP-positive neurons, green; ␤-gal-containing cells, red; and TPH2-positive neurons, blue. These pseudocolored images were then overlaid and colocalization of two or three fluorophores was determined by turning on and off each layer to determine the location and color of each cell.
Neurons expressing different combinations of signals and located within different brainstem nuclei were manually counted from the Photoshop files. Neurons were quantified from six different levels through medulla and midbrain at approximately Ϫ12.7 mm, Ϫ11.6 mm, Ϫ11.0 mm, Ϫ10.3 mm, Ϫ8.7 mm, and Ϫ7.8 mm relative to bregma. Since not every nucleus was present at each level, different numbers of sections were used to quantify the data for each nucleus. Quantification was performed from one section/animal for the caudal, dorsal, ventral, and ventrolateral subdivisions of the dorsal raphe, one section/ animal for ventrolateral periaqueductal gray, one section/ animal for the parapyramidal area, two sections/animal for raphe obscurus, three sections/animal for gigantocellular nucleus pars alpha (ventral and dorsal subdivisions), three sections/animal for raphe magnus, and four sections/animal for raphe pallidus.
To determine fractions of serotonergic cells in different nuclei, tissue in which TPH2 antibody was visualized with diaminobenzidine and counterstained with cresyl violet was used. Cell counts were performed using Stereo Investigator 6.5 software (MicroBrightField, Williston, VT) under a 40ϫ objective. The total number of cells in each nucleus was determined by counting nuclei of all cresyl violet-stained cells and TPH2-positive profiles.
Brightness and contrast of images were optimized for presentation purposes, and figures were prepared in Photoshop.
RESULTS

Specificity of TPH2 antibody
To ascertain the specificity of the TPH2 antibody used in these studies we carried out blocking studies with TPH1, TPH2, and Ki-67 peptides. Under control conditions, in the absence of peptide, there was robust labeling within the dorsal raphe (DR) in the midbrain (Fig.  1A,D,G) but not in the pineal gland (data not shown). This labeling was markedly attenuated when the antibody solution was preadsorbed with 2 M solution of the TPH2 peptide (Fig. 1B) . The labeling was blocked entirely when the concentration of the TPH2 peptide was increased to 5 M (Fig. 1E) . In contrast, preadsorption of the antibody solution with TPH1 peptide had no effect on the signal intensity either at 2 or 5 M (Fig. 1C,F) . Similarly, preadsorption with Ki-67, an unrelated peptide, had no effect on the immunocytochemical labeling within the dorsal raphe (Fig. 1H,I ).
Distribution of TPH2-positive neurons
The distribution of TPH2-positive neurons was examined within the medulla, pons, and midbrain. In the medulla, TPH2-positive neurons were found within a midline column of cells comprised of raphe pallidus (RPa) and raphe obscurus (ROb; Fig. 2A,B, respectively) . At more rostral levels, TPH2-positive neurons appeared more laterally within raphe magnus (RMg; Fig. 2D ), gigantocellular nucleus pars alpha (GiA; Fig. 2E ), as well as the parapyramidal cell group (PPy; Fig. 2C ), located dorsolaterally to the pyramidal tracts. Within GiA, TPH2-positive neurons were preferentially distributed along the ventral aspect of the nucleus. At the level of the pontomedullary junction, TPH2-immunoreactive neurons were found primarily within RMg and RPa (Fig. 2G) and GiA (Fig. 2F) .
TPH2-immunoreactive neurons in the midbrain were concentrated primarily along the midline within DR and median raphe (MnR; Fig. 3A,C) . Additionally, such neurons were also located within laterally displaced clusters within the ventrolateral periaqueductal gray (vlPAG; Fig.  3B,D) .
The fraction of serotonergic neurons in each nucleus was estimated from the material in which TPH2 was visualized with diaminobenzidine and the tissue was counterstained with cresyl violet. In these experiments, the total number of cells was estimated from all detectable cresyl violet-stained nuclei. This quantification revealed considerable variability in the fraction of serotonergic neurons among the different nuclei. These values ranged from 5-33%, depending on the nucleus (Table 1) .
Labeling in the spinal cord
Labeling in the spinal cord was examined in two rats in the short survival group. The goals of these experiments were: 1) to verify the effectiveness of the surgical sympathectomy, and 2) to verify infection of the appropriate first-order neurons in thoracic and lumbar spinal cord. In both animals we detected infection in the ipsilateral gastrocnemius motoneurons with PRV-152 at L3-L4 levels of the spinal cord (Fig. 4A) . We also observed infection of ipsilateral adrenal sympathetic preganglionic neurons within the intermediolateral cell column at mid-thoracic levels with PRV-BaBlu (Fig. 4B) . There was no infection with PRV-152 in the intermediolateral cell column (Fig.  4C) , demonstrating the effectiveness of the surgical sympathectomy.
Expression of TPH2 within PSPMNs
As in our previous studies, we found considerable clusters of PSPMNs within the different subregions of the ventromedial medulla, including ROb, RMg, RPa, GiA, and PPy (Figs. 5-7) . At more rostral levels, clusters of PSPMNs were also found within vlPAG and just lateral to the DR proper (Fig. 8) . This basic distribution pattern was the same for animals at different survival times; however, the numbers of double-infected neurons increased with longer survival times (Figs. 6 -8) . Triple-and doublelabeled neurons were found throughout the brainstem and included neurons within the ventromedial medulla, pons, and caudal midbrain (Fig. 5) .
To estimate whether specific nuclei may vary in their content of triple-labeled neurons, we mapped the locations of double-and triple-labeled cells in each animal at six different rostrocaudal levels (Figs. 6 -8 ). This analysis revealed distinct clustering of neurons infected with one or both strains of PRV that also expressed TPH2. At the caudalmost level that we examined (Ϫ12.7 mm from bregma), such neurons were confined primarily to ROb
The Journal of Comparative Neurology. DOI 10.1002/cne and distributed along the midline (Figs. 5C, 6A ). At the more rostral levels within medulla-pons (Ϫ11.6 mm, Ϫ11.0 mm, and Ϫ10.3 mm from bregma), these neurons fanned out laterally and ventrally and were concentrated within the ventral aspect of GiA and to some extent within RMg and PPy (Figs. 6B,D, 7) . Few of the virus-infected neurons in the midbrain expressed TPH2 at the early survival times. However, at the longer survival times their numbers increased and they were displaced laterally from the midline and found predominantly within vlPAG (Fig. 8C ) and lateral DR (Fig. 8D) .
Estimates of the number of these cells among the different nuclei revealed differences in their distribution. At the caudal levels the greatest numbers of TPH2-positive PSPMNs were found within ROb, RMg, and GiA (Table 1) . At more rostral levels, relatively low numbers of TPH2-positive PSPMNs were detected in the different subdivision of DR and in the vlPAG (Table 1) .
Additionally, we estimated the percentage of PSPMNs that expressed TPH2 within the different nuclei. This analysis revealed that these neurons were enriched in the ventral GiA (Table 1 ). In contrast, dorsal GiA contained a relatively low percentage of TPH2-positive PSPMNs (Table 1).
DISCUSSION
In the current study we focused our attention on brainstem PSPMNs. Neurons with putative dual (sympathetic and somatomotor) functions were identified by injections of distinct PRV recombinants into peripheral muscle and the adrenal gland. Based on our previous reports on the anatomical distribution of the brainstem PSPMNs, we hypothesized that a subset of them would be serotonergic. To test this hypothesis, we designed and produced an antibody against TPH2, a TPH isoform that is specifically Fig. 1 . Characterization of tryptophan hydroxylase 2 (TPH2) antibody. Specificity of binding was ascertained by performing a series of blocking studies. In the first experiment signal was examined under control conditions when tissue was reacted with TPH2 antibody at 1:2,000 (A). Adjacent sections were then reacted with TPH2 antibody pre-adsorbed with 2 M of either TPH2 (B) or TPH1 (C) peptide solution. In the second experiment TPH2 signal (at 1:2,000) was examined under control conditions (D) and after preadsorption of the antibody with 5 M of either TPH2 (E) or TPH1 (F) peptide. In the last experiment TPH2 signal (at 1:2,000) was examined under control conditions (G) and after preadsorption of the antibody with either 1 M (H) or 50 M (I) of Ki-67 (an unrelated peptide). Scale bar ϭ 100 m.
The Journal of Comparative Neurology. DOI 10.1002/cne expressed in the brain (Patel et al., 2004) . Our characterization studies of this antibody demonstrate that the staining produced by this antibody is specific for TPH2 since: 1) the signal was completely blocked by the specific TPH2 peptide but not by TPH1 or Ki-67 peptides, and 2) distribution of immunopositive neurons closely matched the distribution of TPH2 mRNA (Patel et al., 2004) . Thus, we could be confident that the neurons that we detected with this antibody were serotonergic.
Our injections into the muscle and adrenal gland were effective at infecting specific first-order neurons, as demonstrated by the labeling in the spinal cord. Injections of PRV-BaBlu into the adrenal gland produced infection of ipsilateral sympathetic preganglionic neurons at midthoracic levels. This distribution of putative adrenal sympathetic preganglionic neurons is in close agreement with previous studies that demonstrated that these neurons are distributed from T4 to T12 in the spinal cord (Strack et al., 1989; Li et al., 1992; Joshi et al., 1995) . Likewise, we detected PRV-152-infected somatic motoneurons at ipsilateral mid-lumbar spinal levels, which most likely represent gastrocnemius motoneurons since these cells were detected in the same location in previous investigations (Hashizume et al., 1988; Kanda et al., 1989; Kerman et al., 2003) . Furthermore, we can be confident of the effectiveness of the surgical sympathectomy procedure since we did not observe infection with PRV-152 in the intermediolateral cell column in the same animals that showed robust infection of gastrocnemius motoneurons, which is also consistent with our past findings (Kerman et al., 2003 (Kerman et al., , 2006 .
We found considerable overlap between the distribution of TPH2-positive cells and PSPMNs. The distribution of TPH2-expressing PSPMNs differed along the rostrocaudal extent, with peaks in the rostral medulla and at the pontomedullary junction. Likewise, the distribution of these cells differed by nuclei so that ROb, RMg, and GiA contained the greatest numbers of triple-labeled neurons. The fraction of PSPMNs that were TPH2-positive also differed by nuclei. Interestingly, within GiA there was a difference in the location of triple-labeled cells in the dorsoventral extent, with a much greater percentage of such cells located within its ventral compartment. This is consistent with the recent findings of Toth et al. (2006) , who found a differential distribution of serotonergic neurons that innervate the tail in this region. Those authors demonstrated that presympathetic serotonergic cells that innervate the tail are preferentially distributed toward the ventral edge of the ventromedial medulla, with large numbers located just dorsal to the pyramids (Toth et al., 2006) . This finding is in agreement with our data that indicate that a large fraction of serotonergic PSPMNs are located Estimates of the total number of cells per section in each nucleus was derived from cresyl violet-stained sections, indicated in parentheses. Numbers represent totals from all animals normalized to the number of sections used to sample through each nucleus per animal. cDR, caudal dorsal raphe; dDR, dorsal subdivision of dorsal raphe; dGiA, dorsal gigantocellular nucleus pars alpha; PPy, parapyramidal cell group; RMg, raphe magnus; ROb, raphe obscurus; RPa, raphe pallidus; vDR, ventral subdivision of dorsal raphe; vGiA, ventral gigantocellular nucleus pars alpha; vlDR, ventrolateral dorsal raphe.
The Journal of Comparative Neurology. DOI 10.1002/cne within ventral GiA as well as with studies that used monosynaptic tracers and found preferential distribution of spinally projecting serotonergic neurons in the ventral GiA (Skagerberg and Björklund, 1985; Bowker and Abbott, 1990; Jones and Light, 1992) .
When interpreting our quantitative data it is important to keep in mind that these numbers represent estimates.
To obtain more precise data with regard to the total number of TPH2-positive PSPMNs within different nuclei will require more extensive unbiased 3D sampling. Nonetheless, our current estimates suggest differences in the distribution of serotonergic PSPMNs within the brainstem.
Based on our findings, we hypothesize that these serotonergic PSPMNs likely project directly to the spinal cord, and that these projections probably collateralize to simultaneously innervate adrenal sympathetic preganglionic neurons in the thoracic spinal cord and gastrocnemius motoneurons in the lumbar spinal cord. This notion is supported by the fact that we detected TPH2-expressing PSPMNs at the earliest survival time examined in this study. We have previously reported the presence of double-infected neurons in the ventromedial medulla at an even earlier (96-hour postinjection into the gastrocnemius muscle) survival time point (Kerman et al., 2003) . Furthermore, studies employing classical tract-tracing agents have demonstrated direct projections from the ventromedial medulla to the intermediolateral cell column as well as to the ventral horn of the spinal cord in different species (Martin et al., 1979 (Martin et al., , 1985 Zemlan et al., 1984; Holstege and Kuypers, 1987; Allen and Cechetto, 1994) . Others have also demonstrated the presence of serotonergic terminals on motoneurons and sympathetic preganglionic neurons (Appel et al., 1986 (Appel et al., , 1987 Wu et al., 1993) as well as a high density of serotonergic fibers in the lumbar ventral horn and the intermediolateral cell column (Steinbusch, 1981) . However, given the fact that we used a transsynaptic tracer we cannot conclude with certainty that these cells send direct projections to the spinal cord. Future work utilizing monosynaptic tracers will be required to test this hypothesis.
In contrast, relatively fewer triple-labeled neurons were found within the midbrain. Despite the presence of an appreciable number of double-infected neurons, a lesser fraction of PSPMNs was TPH2-positive, especially at the earlier survival times. Nonetheless, our data demonstrate a distinct clustering of TPH2-positive PSPMNs within the vlPAG and vlDR at the later survival times. It is unlikely that these neurons send direct projections to the spinal cord, since their presence is not detected until the later survival times. Instead, it is possible that these cells send projections to the ventral medulla to simultaneously regulate sympathetic and somatomotor functions. This notion is consistent with traditional tract-tracing experiments that have demonstrated projections from the ventral and ventrolateral periaqueductal gray to the ventromedial medulla (Beitz et al., 1983; Van Bockstaele et al., 1991; Beitz, 1995; Farkas et al., 1998) . Fig. 4 . Labeling in the spinal cord following PRV injections into gastrocnemius muscle and adrenal gland. In the same animal we observed PRV-152-infected somatic motoneurons at L4 spinal level ipsilateral to the injected side (A) as well as PRV-BaBlu-infected sympathetic preganglionic neurons in the ipsilateral intermediolateral cell column at T8 (B). These neuronal populations correspond to the gastrocnemius motoneuron pool and adrenal sympathetic preganglionic neurons, respectively. Effectiveness of the surgical sympathectomy was confirmed by the absence of PRV-152-infected neurons in the intermediolateral cell column, an example at the ipsilateral T13 is shown (C). Scale bar 100 m.
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Taken together, our data demonstrate the presence of clusters of serotonergic PSPMNs within the rostral medulla and at the medullopontine junction. Previous studies have investigated the fraction of spinally projecting neurons from the ventromedial medulla that are serotonergic. These estimates have ranged from 30 -60% (Skagerberg and Bjö rklund, 1985; Jones and Light, 1992) of spinally projecting neurons that are serotonergic to over 90% of such cells (Bowker and Abbott, 1990) . Our data (see Table 1 ) suggest that in ROb and RMg ϳ20 -30% of PSPMNs are serotonergic, while in RPa and ventral GiA this fraction is ϳ40 -60%. These data may actually underestimate the true fraction of TPH2-expressing PSPMNs since viral infection inhibits transcription of the host cell genome (Card, 2001) . Nonetheless, these are heterogeneous nuclei that contain neurons of multiple phenotypes. For example, the ventromedial medulla has prominent expression of glutamic acid decarboxylase (GAD) (Stornetta and Guyenet, 1999) , a key synthetic enzyme in the production of GABA, as well as vesicular glutamate transporters (Nakamura et al., 2004) , suggesting that there are populations of glutamatergic and GABAergic cells in this region. Additionally, cells within the ventromedial medulla also express a number of peptidergic transmitters, including enkephalin, thyrotropin-releasing hormone, and substance P (Kerman et al., 2004) . The possibility that the nonserotonergic PSPMNs within GiA express GAD, glutamate, and/or peptide neurotransmitters remains to be explored. 
SYMPATHO-SOMATOMOTOR CIRCUITRY AND TPH2
To determine whether the proportion of TPH2-positive PSPMNs is identical to the proportion of cells that is serotonergic in each nucleus, we estimated the latter from cresyl violet-counterstained tissue. These estimates suggest that the fraction of cells in each nucleus that is serotonergic ranges from 5-33%. These numbers are consistent with previous estimates, which found that ϳ10 -30% of the medullary raphe cells are serotonergic (Moore, 1981; Potrebic et al., 1994) . These estimates also suggest that the number of TPH2-positive PSPMNs is not simply a reflection of the fraction of serotonergic cells in each nucleus. For example, within the ventral subdivision of GiA, 57% of PSPMNs are serotonergic, while only 12% of all cells are serotonergic (Table 1) . Likewise, within ROb and PPy, 26% and 24% of PSPMNs are serotonergic, respectively, while the fraction of serotonergic neurons is 12% and 6%, respectively (Table 1) . Thus, within many of the Fig. 6 . Distribution of double-and triple-labeled neurons within the medulla. Anatomical landmarks were traced from original sections and locations of virus-infected cells were plotted onto these maps. Only one hemisection is presented from each level, but the pattern of labeling was symmetrical. Each symbol represents one neuron on the actual section. Yellow squares represent neurons coinfected with PRV-152 and PRV-BaBlu, black circles: neurons coinfected with PRV-152 and PRV-BaBlu that also express TPH2; red triangles: TPH2-containing neurons that are infected with PRVBaBlu; aqua diamonds: TPH2-containing neurons infected with PRV-152. Panels on the left (A,B) are from animals that survived 122 and 97 hours following injections with PRV-152 and PRV-BaBlu, respectively. Panels on the right (C,D) are from animals that survived 144 and 120 hours following injections with PRV-152 and PRV-BaBlu, respectively. Numbers on the left represent approximate distance in mm from bregma. py, pyramidal tract; RPa, raphe pallidus; ROb, raphe obscurus; PPy, parapyramidal area; GiA, gigantocellular nucleus pars alpha; RMg, raphe magnus.
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Functional considerations
Classically, the ventromedial medulla has been considered to be a pain modulatory area, since activation of this region can produce antinociception (Mason, 2001 ). This notion is supported by the connections of this region, which include neurons with direct projections to the dorsal horn (Mason, 2001) . Our findings suggest that such antinociceptive neurons are intermingled with PSPMNs within the ventromedial medulla; thus, it is possible that activation of this region may coordinate somatomotor, autonomic, and sensory responses to acute pain stimuli. Such a scenario would include activation of PSPMNs to facilitate expression of appropriate somatomotor and autonomic responses as well as concurrent activation of the antinociceptive neurons for simultaneous pain modulation. This is supported by the fact that activation of the ventromedial medulla by injection of kainic acid or morphine elicits immobility together with antinociception (Morgan and Whitney, 2000) . Although autonomic parameters were not measured in that study, our data suggest that such manipulations may also lead to the secretion of adrenal catecholamines. It is also likely that serotonergic neurons of the ventromedial medulla contribute to antinociception since they project to the dorsal horn (Mason, 2005) , and application of serotonin receptor antagonists in the ventromedial medulla attenuates antinociception evoked by ventromedullary stimulation (Hammond and Yaksh, 1984; Barbaro et al., 1985) . However, this action may be dependent on the behavioral state, such as the phase of the sleep/wake cycle (Mason, 2001) . Likewise, serotonergic neurons of the ventromedial medulla identified in the present study may act to coordinate somatomotor and sympathetic functions during responses to acute pain stimuli.
Another functional possibility is that the serotonergic PSPMNs are involved in mediating central responses to exercise. Results of studies in awake behaving cats sug- gest that a major role of the descending serotonergic system is to increase excitability of spinal motoneurons and to facilitate somatomotor output (Jacobs and Fornal, 1997) . More recently, recordings from serotonergic neurons in the caudal raphe nuclei of awake locomoting cats suggest that the decreases in the firing of these neurons may be related to the onset of central fatigue (Fornal et al., 2006) . Thus, the serotonergic PSPMNs may gate excitability of lumbar motoneurons and adrenal sympathetic preganglionic neurons to prevent excessive stress during exercise.
The serotonergic PSPMNs identified in the present study may also play a role in serotonin syndrome, an adverse reaction to intoxication with agents that lead to increased serotonin release such as selective serotonin reuptake inhibitors (Boyer and Shannon, 2005) . This condition is often characterized by somatomotor disturbances such as spasms, shivering, and myoclonus as well as au- tonomic signs such as hypertension, tachycardia, and hyperthermia (Boyer and Shannon, 2005) . This notion is consistent with the finding that disinhibition of the ventromedial medulla in lightly anesthetized rats causes increases in blood pressure, tachypnea, shivering, and an elevation in the temperature of brown adipose tissue (Nason and Mason, 2004) .
Thus, it is possible that under normal conditions serotonergic PSPMNs may mediate physiological responses to acute pain stimuli and exercise, while under pathological conditions they may mediate symptoms of serotonergic intoxication.
